Skip to Content
Merck
CN

SML1608

Besifloxacin hydrochloride

≥98% (HPLC)

Synonym(s):

7-[-3-Aminoazepam-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H21ClFN3O3 · HCl
CAS Number:
1398566-43-2
Molecular Weight:
430.30
UNSPSC Code:
12352200
PubChem Substance ID:
329825494
NACRES:
NA.77
MDL number:
MFCD23712955

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C19H21ClFN3O3.ClH/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23;/h7,9-11H,1-6,8,22H2,(H,26,27);1H

InChI key

PMQBICKXAAKXAY-UHFFFAOYSA-N

SMILES string

[H]Cl.OC(C1=CN(C2CC2)C3=C(Cl)C(N4CCCCC(N)C4)=C(F)C=C3C1=O)=O

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to light brown

solubility

DMSO: 2 mg/mL, clear (warmed)

storage temp.

−20°C

Quality Level

100

Biochem/physiol Actions

Besifloxacin is a broad spectrum fourth-generation fluoroquinolone antibiotic.
Besifloxacin is a broad spectrum fourth-generation fluoroquinolone antibiotic. Besifloxacin is effective against gram positive and negative, aerobic and anerobic bacteria. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV by binding to the enzyme-DNA complex generating persistent, covalent enzyme–DNA adducts, inhibiting DNA synthesis. Besifloxacin inhibits both DNA gyrase and topoisomerase IV at nearly equal concentrations. It is used clinically primarily in the treatment of bacterial conjunctivitis.
Besifloxacin stops the production of pro-inflammatory cytokines in vitro.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000187286
0000178198
0000187286
0000178198
0000040618

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jean Deschênes et al.
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 50(3), 184-191 (2015-06-05)
Acute bacterial conjunctivitis is a common infection of the ocular surface. Increasing rates of bacterial resistance have prompted the development of new antibiotics with improved activity against the bacterial species most often found in this disease. Besifloxacin is the first
Synthetic approaches to the 2009 new drugs
Liu K K C, et al.
Bioorganic & Medicinal Chemistry, 19(3), 1136-1154 (2011)
Alexander T Nguyen et al.
Cornea, 34(8), 967-971 (2015-06-16)
To present the clinical outcome of 3 cases of ocular surface infections by Mycobacterium chelonae treated with besifloxacin (0.6%, Besivance; Bausch & Lomb, Tampa, FL). In this retrospective review of a small case series, we reviewed the medical records of
Timothy L Comstock et al.
Clinical ophthalmology (Auckland, N.Z.), 4, 215-225 (2010-05-14)
Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is critical in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service